Cellectis (CLLS) Non Operating Income (2021 - 2022)
Cellectis (CLLS) posted quarterly Non Operating Income of -$7.4 million for Q1 2026, down 88.68% year-over-year from -$65.8 million in Q1 2025, and down 143.52% quarter-over-quarter from $17.1 million in Q4 2025.
Analysis
Cellectis (CLLS) Non Operating Income (2021 - 2022) Analysis & Trends
Cellectis' Non Operating Income history runs 12 years deep, the most recent figure standing at -$7.4 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 88.68% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$11.9 million (down 60.65% YoY), while the FY2025 annual figure was -$34.9 million, down 253.29% from the prior year.
- Non Operating Income for Q1 2026 stood at -$7.4 million, down from $17.1 million in the prior quarter.
- The five-year high for Non Operating Income was $17.1 million in Q4 2024, with the low at -$26.3 million in Q1 2024.
- The 5-year median for Non Operating Income is -$5.8 million (2023), against an average of -$5.3 million.
- Peak annual rise in Non Operating Income reached 301.04% in 2022, while the deepest fall reached 737.74% in 2022.
- Cellectis' Non Operating Income stood at -$20.0 million in 2022, then plunged by 30.87% to -$26.1 million in 2023, then surged by 165.54% to $17.1 million in 2024, then changed by 0.0% to $17.1 million in 2025, then slumped by 143.52% to -$7.4 million in 2026.
- Business Quant data shows CLLS's Non Operating Income at -$7.4 million in Q1 2026, $17.1 million in Q4 2025, and -$7.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | - |